Medication info
Iberprofen 150/12.5 mg

Iberprofen 150/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Irbesartan›150mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Samchundang Pharmaceutical Co., Ltd.
Appearance
Pink oval coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200705219 · Notified 2007.05.07 · Insurance code 651201480

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
This medicine is administered once daily, with or without food. Dose titration for each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - For patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be administered in combination with other antihypertensive agents. 2. When this medicine is to be used as initial therapy in patients with moderate or severe hypertension (stage 2), treatment should be individualized, taking into consideration baseline blood pressure, target blood pressure, and the expected increase in the likelihood of reaching the treatment goal compared with monotherapy. Treatment is usually initiated with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily, and the dose may be increased after 1 ~ 2 weeks, up to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg, if blood pressure control is needed. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in these patients. No dose adjustment is necessary in patients with renal impairment and a creatinine clearance of 30 mL/min or more. ○ Patients with volume depletion If sodium and/or fluid has been depleted, the imbalance should be corrected before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide medicines should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Older adults No dose adjustment is necessary in older adults.
Child dose
○ Children The safety and efficacy of this medicine have not been established in children and adolescents younger than 18 years.

Ingredients

Manufacturer
Samchundang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
  • moderate hypertension
  • severe hypertension
View approved original text

Essential hypertension is a condition characterized by elevated blood pressure, which increases the risk of cardiovascular diseases. In some patients, blood pressure may be difficult to control with a single medication; in such cases, combination therapy is used to manage blood pressure more effectively. Especially in patients with moderate to severe hypertension, initial treatment with combination therapy is necessary to rapidly and accurately lower blood pressure. This approach helps to stabilize blood pressure control, prevent complications, and improve overall health. Therefore, appropriate treatment methods are selected based on the patient's condition for blood pressure management.

How to take

Adult dose

This medicine is administered once daily, with or without food. Dose titration for each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - For patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be administered in combination with other antihypertensive agents. 2. When this medicine is to be used as initial therapy in patients with moderate or severe hypertension (stage 2), treatment should be individualized, taking into consideration baseline blood pressure, target blood pressure, and the expected increase in the likelihood of reaching the treatment goal compared with monotherapy. Treatment is usually initiated with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily, and the dose may be increased after 1 ~ 2 weeks, up to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg, if blood pressure control is needed. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in these patients. No dose adjustment is necessary in patients with renal impairment and a creatinine clearance of 30 mL/min or more. ○ Patients with volume depletion If sodium and/or fluid has been depleted, the imbalance should be corrected before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide medicines should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Older adults No dose adjustment is necessary in older adults.

Child dose

○ Children The safety and efficacy of this medicine have not been established in children and adolescents younger than 18 years.

Precautions

This medication can cause serious harm to the fetus or newborn if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, nursing mothers, patients with anuria, and patients with severe renal impairment should not take this medication. Patients allergic to any components of this medication or those with certain genetic disorders should also avoid taking it. Patients with hypotension, abnormal kidney function, liver impairment, certain heart conditions, acute closed-angle glaucoma, or a history of skin cancer should use this medication with caution. Side effects such as dizziness, fatigue, nausea, vomiting, and abnormal urination may occur; patients should consult a doctor if symptoms are severe. There may be an increased risk of skin cancer, so it is advisable to limit sun exposure and inform a doctor immediately if any skin abnormalities occur. Caution is required when driving or operating machinery, as dizziness or fatigue may occur. While this medication lowers blood pressure, hypotension might occur in cases of sodium or fluid depletion, necessitating a review of the patient's condition before administration. Patients with poor kidney function should have serum potassium and creatinine levels monitored periodically, and patients with liver impairment should use this medication cautiously. This medication may affect blood glucose and lipid levels, so diabetic patients may need to adjust their treatment doses accordingly. Electrolyte imbalances can occur; if symptoms such as dry mouth, thirst, or muscle cramps appear, patients should consult their doctor immediately. Acute closed-angle glaucoma symptoms may arise; if eye pain or vision changes occur, stop this medication and visit a hospital. There may be interactions with other drugs, so especially if taking lithium, potassium supplements, diuretics, antidiabetic drugs, or NSAIDs, patients must consult a doctor or pharmacist. It is generally safer not to take this medication during breastfeeding, and it is not recommended for children and adolescents. Overdosage may lead to hypotension, electrolyte imbalances, dehydration, and other risks, so adherence to the prescribed doses is crucial; if any abnormal symptoms appear, seek medical attention immediately. Keep out of reach of children and store in the original container to maintain drug quality.

Side effects

  • Dizziness
  • fatigue
  • nausea
  • vomiting
  • abnormal urination
  • elevated BUN
  • increased creatine kinase
  • elevated creatinine
  • orthostatic dizziness
  • headache
Show 81 more
  • syncope
  • hypotension
  • tachycardia
  • edema
  • flushing
  • cough
  • diarrhea
  • dyspepsia
  • dysgeusia
  • jaundice
  • hepatitis
  • abnormal liver function
  • sexual dysfunction
  • changes in libido
  • renal impairment
  • limb edema
  • arthralgia
  • myalgia
  • tinnitus
  • angioedema
  • rash
  • urticaria
  • hyperkalemia
  • decreased serum potassium
  • decreased serum sodium
  • hypotension
  • shingles
  • colon cancer
  • hematoma
  • anaphylactic shock
  • anaphylactic reaction
  • intestinal angiopathy
  • anemia
  • thrombocytopenia
  • hypoglycemia
  • depression
  • sleep disturbances
  • orthostatic hypotension
  • arrhythmia
  • aplastic anemia
  • bone marrow suppression
  • neutropenia
  • agranulocytosis
  • hemolytic anemia
  • leukopenia
  • thrombocytopenia
  • dyspnea
  • pancreatitis
  • loss of appetite
  • constipation
  • gastric irritation
  • sialadenitis
  • appetite loss
  • interstitial nephritis
  • renal dysfunction
  • jaundice
  • transient blurred vision
  • xanthopsia
  • weakness
  • muscle spasm
  • anaphylactoid reaction
  • toxic epidermal necrolysis
  • necrotizing vasculitis
  • skin erythematous lupus-like reaction
  • skin erythematous lupus reactivation
  • photosensitivity reaction
  • rash
  • urticaria
  • fever
  • electrolyte imbalance
  • hyperuricemia
  • diabetes
  • hyperglycemia
  • elevated cholesterol
  • increased triglycerides
  • hypokalemia
  • hyponatremia
  • vomiting
  • drowsiness
  • muscle cramps
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in an airtight container. The recommended storage temperature is between 1°C and 30°C (room temperature). Proper storage will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Pink oval coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.